RedHill Biopharma (RDHL) Finished Goods (2017 - 2024)

RedHill Biopharma (RDHL) has reported Finished Goods for 8 consecutive years, with $2.8 million the latest figure, recorded in Q4 2024.

• On a quarterly basis, Finished Goods fell 14.96% year-over-year to $2.8 million in Q4 2024; TTM through Dec 2024 was $2.8 million, a 14.96% decrease from a year earlier, with the FY2024 full-year figure at $2.8 million, down 14.96% from the prior year.
• Finished Goods was $2.8 million for Q4 2024 at RedHill Biopharma, down from $3.3 million in the prior quarter.
• Over five years, Finished Goods peaked at $6.8 million in Q4 2022 and troughed at $2.8 million in Q4 2024.
• A 5-year average of $4.9 million and a median of $4.7 million in 2020 frame the typical range for Finished Goods.
• Across the five-year window, Finished Goods surged 1521.23% in 2020 and sank 51.25% in 2023, its largest moves.
• Over 5 years, Finished Goods stood at $4.7 million in 2020, then surged by 39.48% to $6.6 million in 2021, then rose by 3.39% to $6.8 million in 2022, then slumped by 51.25% to $3.3 million in 2023, then fell by 14.96% to $2.8 million in 2024.
• The last three Finished Goods figures came in at $2.8 million (Q4 2024), $3.3 million (Q4 2023), and $6.8 million (Q4 2022), per Business Quant data.